End Stage Renal Disease
Conditions
Keywords
phosphate binder adherence, autonomous motivation
Brief summary
Hyperphosphatemia in end-stage renal disease (ESRD) patients is a non-traditional risk factor for all-cause and cardiovascular mortality. Non-adherence to phosphate binders is as high as 74% in ESRD patients and has been shown to be most related to psychosocial factors including attitudes. There is limited data on the influence of attitudes and perceived autonomy support on phosphate binder adherence and these two psychosocial constructs can be positively influenced through the use of motivational interviewing skills to increase autonomous motivation. Furthermore, racial disparities are known to exist in ESRD however and there are still gaps, which exist in understanding the determinants of disparities in adherence in vulnerable patients with ESRD. In this study, the investigators seek to determine the impact of motivational interviewing on phosphate binder adherence in diverse ESRD patients. The investigators will ask all the subjects to fill out surveys mainly regarding their attitudes; perceived providers' autonomy support and phosphate binder adherence. The investigators will administer motivational counseling to subjects in the intervention arm of the study, at baseline and 1 month after recruitment. The investigators will ask all the subjects to fill out the same surveys 2 months after recruitment and the investigators will compare subjects who underwent motivational interviewing to those who did not.
Interventions
BEHAVIORALMotivational interviewing
Motivational interviewing counselling sessions will be administered to the subjects.
Sponsors
Vanderbilt University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults age 18 years or older * Receiving phosphate binder therapy currently * English speaking
Exclusion criteria
* Non- English speaking * Known diagnosis of psychosis or dementia, limiting ability to provide informed consent * Any medical condition that precludes participation in the study including deafness, dying etc. * Initial Morisky Medication Adherence score greater than 6
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in subjects' adherence to phosphate binders | baseline and 2 months | Change from baseline in the following survey at 2 months: \- Morisky Medication Adherence Scale (MMAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in attitudes towards phosphate binder therapy | baseline and 2 months | Change from baseline in the following survey/questionnaire at 2 months: \- Autonomous Regulation Scale (AR) |
| change in perceived providers' autonomy support towards phosphate binder therapy | baseline and 2 months | Change from baseline in the following survey/questionnaire at 2 months: \- Health Care Climate Questionnaire (HCC) |
Countries
United States
Outcome results
None listed